Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO), announced that it will serve as the commercial manufacturer for the humanized monoclonal antibody portion of ZYNLONTA™ (loncastuximab tesirine-lpyl), a recently approved cancer treatment developed by ADC Therapeutics. Avid has provided clinical manufacturing services to ADC Therapeutics to support the development of the product since 2017 and will now expand its manufacturing relationship with ADC Therapeutics to include commercial manufacturing activities for ZYNLONTA.
ZYNLONTA is an antibody-drug-conjugate (ADC) composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. In April 2021, ADC Therapeutics received U.S. Food and Drug Administration (FDA) approval for ZYNLONTA for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.
“We are delighted to expand our relationship with the team at Avid as they have significant experience producing monoclonal antibodies,” said Mike Mulkerrin, VP, Head of Chemistry, Manufacturing and Control of ADC Therapeutics. “Avid has been a trusted and responsive manufacturing partner for the last four years and we look forward to collaborating with them in this next phase of our work to bring ZYNLONTA to more patients in need of a new therapeutic option.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!